

Sakaguchi T, Matsuura H, <b>Horie M.</b>	the splicing process.				
Hayashi H, <b>Horie M.</b>	Heritability of early repolarization: A population-based study.	Circulation Cardiovascular Genetics	4(5)	e20	2011
Kimura H, Mizusawa Y, Itoh H, Miyamoto A, Kawamura M, Kawaguchi T, Naiki N, Oka Y, Ohno S, Makiyama T, Ito M, <b>Horie M.</b>	Carvedilol, a non-selective $\beta$ -with $\alpha$ 1-blocker is effective in long QT syndrome type2.	Journal of Arrhythmia	27	324-331	2011
Miyamoto A, Hayashi H, Ito M, <b>Horie M.</b> 22; 350, 2011.	Remission of abnormal conduction and repolarization in the right ventricle after chemotherapy in patients with anterior mediastinal tumor.	J Cardiovasc Electrophysiol.	22	350	2011
佐野 幹、渡邊栄一、牧山武、内山達司、祖父江嘉洋、奥田健太郎、山本真由美、堀江 稔、尾崎行男	ペースメーカー植え込み同胞霊位認められた新たな Lamin A/C 変異	心電図	31(1)	18-24	2011
伊藤英樹、堀江 稔、井本敬二	遺伝性不整脈疾患とシミュレーション。	不整脈+PLUS	3	9	2011
定 翼、国分則人、堀江 稔、阿部百佳、駒ヶ嶺朋子、平田幸一	KCNJ2 変異を伴う Andersen-Tawil 症候群の神経生理所見。	臨床神経生理学	39(1)	18-23	2011
堀江 稔	循環器疾患における遺伝的背景と発症機序理解のための多面的アプローチ	循環器内科	70	421-422	2011
脇坂啓子、堀江 稔	スプライシング異常と循環器疾患	循環器内科	70	523-529	2011
田中正道、永瀬聡、草野研吾 他	左室心外膜にて著明なJ波とOut of QRS potentialが記録されたBrugada症候群 (J wave syndrome)の1例	臨床心臓電気生理	34	205-215	2011
<b>Kusano, KF</b>	High risk ECG in asymptomatic patients with Brugada syndrome.	Circ J	75	777-778	2011
Tanaka M, Nakamura K, <b>Kusano KF</b> et al	Elevated oxidative stress is associated with ventricular fibrillation episodes in patients with brugada-type electrocardiogram without scn5a mutation.	Cardiovascular pathology	20	e37-42	2011
Take Y, Morita H, <b>Kusano KF</b> et al	Spontaneous electrocardiogram alterations predict ventricular fibrillation in brugada syndrome.	Heart rhythm	8	1014-1021	2011
草野研吾	Brugada症候群に合併したVF stormに対するベプリジルの効果	ベプリジル研究会2011記録集		8-9	2011
榎本善成、野呂真人、伊藤尚志、久次米真吾、森山明義、熊谷賢太、酒井 毅、坂田隆夫、杉 薫	Brugada型心電図所見を呈し不整脈源性右室心筋症との関連が示唆された2症例	心臓	Vol 4 4. No.4	456-462	2012
Hiratsuka A, <b>Shimizu A</b> , Uekyama T, Yoshiga Y, Doi M, Ohmiya T, Yoshida	Characteristic of induced ventricular fibrillation cycle length in symptomatic Brugada syndrome	Cir J	76 (3)	624-633	2012

M, Fukuda M, Matsuzaki M					
Aiba T, <b>Shimizu W</b>	Editorial Commentary. Molecular screening of long-QT syndrome: risk is there or rare?	Heart Rhythm	8	420-421	2011
Goldenberg I, Horr S, Moss AJ, Lopes CM, Barsheshet A, McNitt S, Zareba W, Andrews ML, Robinson JL, Locati EH, Ackerman MJ, Benhorin J, Kaufman ES, Napolitano C, Platonov PG, Priori SG, Qi M, Schwartz PJ, <b>Shimizu W</b> , Towbin JA, Vincent GM, Wilde AA, Zhang L	Risk for Life-threatening cardiac events in patients with genotype -confirmed long-QT syndrome and normal-range corrected QT intervals.	J Am Coll Cardiol	57	51-59	2011
Jons C, O-Uchi J, Moss AJ, Reumann M, Rice JJ, Goldenberg I, Zareba W, Wilde AA, <b>Shimizu W</b> , Kanters JK, McNitt S, Hofman N, Robinson JL, Lopes CM:	Use of mutant-specific ion channel characteristics for risk stratification of long QT syndrome patients.	Sci Transl Med	3	76ra28	2011
Migdalovich D, Moss AJ, Lopes CM, Costa J, Ouellet G, Barsheshet A, McNitt S, Polonsky S, Robinson JL, Zareba W, Ackerman MJ, Benhorin J, Kaufman ES, Platonov PG, <b>Shimizu W</b> , Towbin JA, Vincent GM, Wilde AA, Goldenberg I	Mutation and gender specific risk in type-2 long QT syndrome: Implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome.	Heart Rhythm	8	1537-1543	2011
van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt S, <b>Shimizu W</b> , Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborde J, Haïssaguerre M, Knollmann BC, Wilde AAM	Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.	J Am Coll Cardiol	57	2244-2254	2011
Miyoshi T, Maeno Y, Sago H, Inamura N, Yasukochi S, Kawataki M, Horigome H, Yoda H, Taketazu M, Shozu M, Nii M, Kato H, Hayashi S, Hagiwara A, Omoto A, <b>Shimizu W</b> , Shiraishi I, Sakaguchi H, Nishimura K, Ueda K, Katsuragi S, Ikeda T	Evaluation of transplacental treatment for fetal congenital bradycardia: A nationwide survey in Japan.	Circ J	76	469-476	2012
Costa J, Lopes CM, Barsheshet A, Moss AJ, Migdalovich D, Ouellet G, McNitt S, Polonsky S, Robinson JL, Zareba W, Ackerman MJ, Benhorin J, Kaufman ES, Platonov PG, <b>Shimizu W</b> , Towbin JA, Vincent GM, Wilde AA, Goldenberg I	Combined assessment of gender and mutation-specific information for risk stratification in type 1 long QT syndrome.	Heart Rhythm	9		2012 (in press)
Baranchuk A, Nguyen T, Ryu MH, Femenía F, Zareba W, Wilde AAM, <b>Shimizu W</b>	Brugada phenocopy: new terminology and proposed classification.	Ann Noninvasive Electrocardiol			2012 (in press)

<b>zu W</b> , Brugada P, Pérez-Riera AR					
Nakashima K, Kusakawa I, Yamamoto T, Hirabayashi S, Hosoya R, <b>Shimizu W</b> , Sumitomo N	A left ventricular noncompactio n in a patient with long QT syndrome caused by a KCNQ1 mutation: a case report.	Heart Vessels			2012 (in press)
Barsheshet A, Goldenberg I, O-Uchi J, Moss AJ, Christian Jons C, <b>Shimizu W</b> , Wilde AA, McNitt S, Peterson DR, Zareba W, Robinson JL, Ackerman M J, CypressM, Gray DA, Hofman N, Kanters JK, Kaufman ES, Platonov PG, Qi M, Towbin JA, VincentGM, Lopes CM	Mutations in cytoplasmic loops of the KCNQ1 channel and their risk of life-threatening events. Implications for mutation-specific response to beta-blocker therapy in type-1 long QT syndrome.	Circulation			2012 (in press)
Kawarai H, Kajimoto K, Minami Y, <b>Hagiwara N</b> , Kasanuki H.	Risk of sudden death in end-stage hypertrophic cardiomyopathy.	J Card Fail.	17(6)	459-64	2011
Ando K, Koyama J, Abe Y, Sato T, Shoda M, Soga Y, Nobuyoshi M, Honda T, Nakao K, Terata K, Kadowaki K, Maeda A, Ogiwa S, Manaka T, <b>Hagiwara N</b> , Doi K.	Feasibility evaluation of a remote monitoring system for implantable cardiac devices in Japan.	Int Heart J.	52(1)	39-43	2011
Shiga T, Suzuki A, Naganuma M, Hosaka F, Shoda M, <b>Hagiwara N</b> .	Clinical outcome in patientswith paroxysmal or persistent atrial fibrillation receiving bepridil.	Circ J.	75(6)	1334-42.	2011
Matsuura K, Masuda S, Haraguchi Y, Yasuda N, Shimizu T, <b>Hagiwara N</b> , Zandstra PW, Okano T.	Creation of mouse embryonic stem cell-derived cardiac cell sheets.	Biomaterials.	32(30)	7355-62.	2011
Suzuki T, Shiga T, Kuwahara K, Kobayashi S, Suzuki S, NishimuraK, Suzuki A, Omori H,Mori F, Ishigooka J, Kasanuki H, <b>Hagiwara N</b> .	Depression and outcomes in hospitalized Japanese patients with cardiovascular disease. – Prospective single-center observational study-.	Circ J.	75(10)	2465-73.	2011
Fukushima K, Momose M,Kondo C, <b>HagiwaraN</b> , Sakai S.	Accelerated BMIPP uptake immediately after reperfused ischemia in the isolated rat heart model.	Ann Nucl Med.	25(8)	560-5.	2011
Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, Nakajima T, Kawashiro N, Kawana M, <b>Hagiwara N</b> .	Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy.	J Am Coll Cardiol.	57(23)	2346-55.	2011
Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, Dens J, <b>Hagiwara N</b> , Allocco DJ, Dawkins KD; PLATINUM Trial	A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting	J Am Coll Cardiol.	57(16)	1700-8.	2011

Investigators.	Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.				
Momose M, Okayama D, Nagamatsu H, Kondo C, <b>Hagiwara N</b> , Sakai S.	Long-term prognostic stratification by a combination of (123)I-metaiodobenzylguanidine scintigraphy and ejection fraction in dilated cardiomyopathy.	Ann Nucl Med.	25(6)	419-24	2011
Higashitani M, Mori F, Yamada N, Arashi H, Kojika A, Hoshi H, Minami Y, Yamaguchi J, Yamauchi T, Takagi A, Ogawa H, <b>Hagiwara N</b> .	Efficacy of paclitaxel-eluting stent implantation in hemodialysis patients.	Heart Vessels.	26(6):	582-9.	2011.
Kanai S, Uto K, Honda K, <b>Hagiwara N</b> , Oda H.	Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats.	Atherosclerosis.	215(1)	43-51.	2011
Matsuura K, <b>Hagiwara N</b> .	The pleiotropic effects of ARB in vascular endothelial progenitor cells.	Curr Vasc Pharmacol.	9(2)	153-7.	2011

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
<b>鎌倉 史郎</b>	植込み型除細動器	山口徹・北原光夫・福井次夫	今日の治療指針 2011年版	医学書院	東京	2011	332-333
<b>鎌倉 史郎</b>	Brugada 症候群:up-to date.	井上博	別冊・医学のあゆみ, ここまで進んだ不整脈研究の最前線	医歯薬出版	東京	2011	89-94
<b>堀江 稔</b>	QT 短縮症候群	井上 博	別冊医学のあゆみ ここまで進んだ不整脈研究の最新動向	医歯薬出版株式会社	東京	2011	105-108
Hayashi H, <b>Horie M</b> .	Prognostic value of P wave for developing atrial fibrillation.	Jong-Il Choi	Atrial Fibrillation - Basic Research and Clinical Applications	INTECH	クロアチア	2011	189-198
<b>堀江 稔</b>	15章 細胞内灌流法	岡田泰伸	最新パッチクランプ実験技術法	吉岡書店	京都	2011	145-152
<b>Shimizu W</b>	Diagnostic evaluation of Long QT syndrome	Priori SG	Cardiac electrophysiology clinics	Elsevier	Philadelphia	2012 (in press)	
<b>Shimizu W, Ackerman MJ</b>	Clinical rhythmology: Diagnostic methods and tools	Gussak I, Antzelevitch C, Wilde A, Powell B, Ackerman MJ,	Electrical Diseases of the Heart (Second edition)	Springer	UK	2012 (in press)	

		Shen WK (eds)					
<u>Shimizu W</u>	Secondary Hereditary and Acquired Cardiac Channelopathies, and Sudden Cardiac Death	Gussak I, Antzelevitch C, Wilde A, Powell B, Ackerman MJ, Shen WK (eds)	Electrical Diseases of the Heart (Second edition)	Springer	UK	2012 (in press)	
<u>清水 渉</u>	I-7. 無症状のBrugada型心電図: どうする!?(分担)	山下武志 高橋 淳 栗田隆志	不整脈診療のトラブルシューティング	南江堂	東京	2011	24-27
<u>清水 渉</u>	I-8. QT延長症候群・QT短縮症候群の診断はどうする!?(分担)	山下武志 高橋 淳 栗田隆志	不整脈診療のトラブルシューティング	南江堂	東京	2011	28-31
<u>清水 渉</u>	Brugada症候群. 6.循環器疾患 (分担)	山口 徹 北原光夫 福井次矢	『今日の治療指針』2012年版	医学書院	東京	2012	352-353
<u>清水 渉</u>	5. 循環器系の疾患. 5.4 循環器疾患と遺伝子異常. 3) 遺伝性不整脈. (分担)	矢崎義雄 永井良三	朝倉『内科学』	朝倉書店	東京	2012 (印刷中)	
<u>萩原 誠久、 小川 洋司、 笠貫 宏</u>	HIJ-CREATE	熊谷裕生, 小室一成, 堀内正嗣, 森下竜一	高血圧ナビゲーター 第3版	メディカルレビュー社	東京		234-235

## IV. 研究成果の刊行物・別刷り

# Clinical impact of the number of extrastimuli in programmed electrical stimulation in patients with Brugada type 1 electrocardiogram

Hisaki Makimoto, MD, Shiro Kamakura, MD, PhD, Naohiko Aihara, MD, Takashi Noda, MD, PhD, Ikutaro Nakajima, MD, Teruki Yokoyama, MD, Atsushi Doi, MD, PhD, Hiro Kawata, MD, Yuko Yamada, MD, Hideo Okamura, MD, Kazuhiro Satomi, MD, PhD, Takeshi Aiba, MD, PhD, Wataru Shimizu, MD, PhD

*From the Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.*

**BACKGROUND** Use of programmed electrical stimulation (PES) for risk stratification of Brugada syndrome (BrS) is controversial.

**OBJECTIVE** To elucidate the role of the number of extrastimuli during PES in patients with BrS.

**METHODS** Consecutive 108 patients with type 1 electrocardiogram (104 men, mean age  $46 \pm 12$  years; 26 with ventricular fibrillation [VF], 40 with syncope, and 42 asymptomatic) underwent PES with a maximum of 3 extrastimuli from the right ventricular apex and the right ventricular outflow tract. Ventricular arrhythmia (VA) was defined as VF or nonsustained polymorphic ventricular tachycardia  $>15$  beats. Patients with VA induced by a single extrastimulus or double extrastimuli were assigned to group SD (Single/Double), by triple extrastimuli to group T (Triple), and the remaining patients to group N.

**RESULTS** VA was induced in 81 patients (VF in 71 and polymorphic ventricular tachycardia in 10), in 4 by a single extrastimulus, in 41 by double extrastimuli, and in 36 by triple extrastimuli. During  $79 \pm 48$  months of follow-up, 24 patients had VF events. Although the overall inducibility of VA was not associated with an increased risk of VF (log-rank  $P = .78$ ), group SD had worse prognosis than did group T ( $P = .004$ ). Kaplan-Meier analysis in patients without prior VF also showed that group SD had poorer outcome than did group T and group N ( $P = .001$ ). Positive and

negative predictive values of VA induction with up to 2 extrastimuli were, respectively, 36% and 87%, better than those with up to 3 (23% and 81%, respectively).

**CONCLUSIONS** The number of extrastimuli that induced VA served as a prognostic indicator for patients with Brugada type 1 electrocardiogram. Single extrastimulus or double extrastimuli were adequate for PES of patients with BrS.

**KEYWORDS** Brugada syndrome; Programmed electrical stimulation; Number of extrastimuli; Risk stratification; Sudden death

**ABBREVIATIONS** BrS = Brugada syndrome; ECG = electrocardiogram; ICD = implantable cardioverter-defibrillator; LAS40 = duration of low-amplitude signals  $<40 \mu\text{V}$  of the filtered QRS complexes; NPV = negative predictive value; PES = programmed electrical stimulation; PPV = positive predictive value; PVT = polymorphic ventricular tachycardia; RVA = right ventricular apex; RVOT = right ventricular outflow tract; RMS40 = root mean square voltage of the terminal 40 ms of the filtered QRS complexes; VA = ventricular arrhythmia; VF = ventricular fibrillation

(Heart Rhythm 2012;9:242-248) © 2012 Heart Rhythm Society. All rights reserved.

## Introduction

Brugada syndrome (BrS) is a channelopathy that can cause sudden death due to ventricular fibrillation (VF) in apparently healthy individuals in their prime. Since Brugada et al

reported it first in 1992, several indices have been reported as reliable prognostic factors.<sup>1-6</sup> However, there remains much room for debate in prognostic indices except for history of VF.<sup>7</sup> Although induction of lethal ventricular

This work was supported by a research grant for the cardiovascular diseases (grant number H23-114, 22-1-2) from the Ministry of Health, Labor, and Welfare, Japan, and a grant from Japan Cardiovascular Research Foundation. Dr Shimizu was supported in part by a research grant for the cardiovascular diseases (grant number 21C-8, 22-4-7) from the Ministry of Health, Labor, and Welfare, Japan, and a Grant-in-Aid for Scientific Research on Innovative Areas (grant number 22136011). Presented in part at the American Heart Association 2010, Chicago, IL, November 13-17,

2010, and published in abstract form in *Circulation* 2010;122:A15371.

**Address reprint requests and correspondence:** Dr Shiro Kamakura, MD, PhD, Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. E-mail address: kamakura@hsp.ncvc.go.jp.

arrhythmia (VA) by programmed electrical stimulation (PES) is still widely adopted for deciding the indication of an implantable cardioverter-defibrillator (ICD), controversial data have been reported regarding its prognostic value.<sup>2,4,7-9</sup> Brugada et al reported that VF inducibility by PES can be a strong predictor of subsequent cardiac events in patients with BrS.<sup>8</sup> However, other studies could not confirm these findings.<sup>2,4,7</sup> Because protocols of PES and backgrounds of patients were different in each study, direct comparison of the results was not possible. Moreover, clinical significance of the number of extrastimuli, the site of induction, and the coupling interval of extrastimuli at the time of VF induction by consistent protocol have not been fully elucidated.

The aim of the present study was to test the hypothesis that subsequent cardiac events occur more frequently in patients with BrS with induction of VAs by fewer extrastimuli during PES. Thus, we examined the relationships of several parameters of PES, especially the number of extrastimuli, the site of induction, and the coupling interval of extrastimuli at the time of VF induction, with subsequent cardiac events.

## Methods

### Study population

The study population consisted of consecutive 108 Japanese patients with Brugada type 1 electrocardiogram (ECG) in the absence or presence of sodium-channel-blocking agent (104 men, mean age  $46 \pm 12$  years) who underwent electrophysiological study at National Cerebral and Cardiovascular Center, Suita, Japan, between 1993 and 2009. Twenty-six patients had a history of VF, 40 had a history of syncope, and 42 were asymptomatic at the time of the electrophysiological study. Patients' characteristics are

**Table 1** Overall clinical and electrocardiographic characteristics of 108 patients

Characteristics	N (%)
<b>Clinical</b>	
Male	104 (96%)
Age (y)	$46 \pm 12$
Hx of VF	26 (24%)
Hx of syncope	40 (37%)
Asymptomatic	42 (39%)
Family Hx of BrS	6 (6%)
Family Hx of SD under age 45 y	22 (20%)
Age at first CE (y)	$43 \pm 14$
<b>Electrocardiographic</b>	
RR interval (ms)	$971 \pm 118$
PQ interval (ms)	$176 \pm 29$
QRS duration (ms)	$96 \pm 16$
Corrected QT interval (ms)	$405 \pm 29$
Spontaneous coved-type ST segment	62 (57%)
Total filtered QRS duration	$119 \pm 17$
LAS40	$47 \pm 16$
RMS40	$16 \pm 11$

BrS = Brugada syndrome; CE = cardiac event; Hx = history; SD = sudden death; VF = ventricular fibrillation.

shown in Table 1. Two patients with nocturnal agonal respiration were included in VF patients.

Brugada type 1 ECG was diagnosed when a coved ST-segment elevation ( $\geq 0.2$  mV at J point) was observed in more than one of the right precordial leads (V1–V3) in the presence or absence of a sodium-channel-blocking agent. Sixty-two patients exhibited spontaneous type 1 ECG, and the rest of the patients showed type 2 or 3 ECG at baseline and type 1 ECG after administration of 1 mg/kg of pilsicainide. Obvious type 1 ECG ( $>2$  mm J-point elevation followed by  $>3$  mm ST elevation in precordial leads) was confirmed after pilsicainide administration in all patients with drug-induced type 1 ECG. Patients were diagnosed as suffering from BrS according to the report of the second consensus conference.<sup>10</sup>

### Clinical information

History taking, physical examinations, chest roentgenogram, and ECG were conducted. All participants underwent echocardiography to exclude structural heart disease. Clinical information including age, sex, family history, and age of first cardiac event was collected. Twelve-lead ECG was recorded in all 108 patients, and the RR interval, PR interval (lead II), QRS duration (lead V5), and corrected QT interval (lead V2) were measured. Signal-averaged ECG was recorded and analyzed in 91 patients by using a signal-averaged ECG system (Arrhythmia Research Technology 1200EPX, Milwaukee, WI). Three parameters were assessed by using a computer algorithm: (1) total filtered QRS duration, (2) root mean square voltage of the terminal 40 ms of the filtered QRS complexes (RMS40), and (3) duration of low-amplitude signals  $<40 \mu\text{V}$  of the filtered QRS complexes (LAS40). Late potential was considered positive when the 2 criteria ( $\text{RMS40} < 18 \mu\text{V}$  and  $\text{LAS40} > 38$  ms) were fulfilled. Genetic test for the presence of an *SCN5A* mutation was also performed by direct sequencing, and the entire coding sequence of the *SCN5A* gene was thoroughly searched.

### Electrophysiological study

An electrophysiological study was conducted in fasting and nonsedated state after written informed consent. None of the patients received antiarrhythmic drugs before the electrophysiological study. The atrio-His and His-ventricular intervals were measured during sinus rhythm. We defined the induction of VA as an induction of VF or nonsustained polymorphic ventricular tachycardia (PVT) of more than 15 consecutive beats. A maximum of 3 programmed ventricular extrastimuli were delivered from the right ventricular apex (RVA) and the right ventricular outflow tract (RVOT), unless VA was induced. First, single extrastimulus and double extrastimuli were delivered from the RVA followed by the RVOT. Next, triple extrastimuli was delivered from the RVA followed by the RVOT. The basic cycle length was 500 ms. The coupling interval was reduced in decrements of 10 ms until ventricular refractoriness, coupling interval reached 180 ms, or VF was induced.

We divided the study subjects into 3 groups according to the results of the PES. Patients with VA induced by a single extrastimulus or double extrastimuli were assigned to group



SD, by triple extrastimuli to group T, and noninducible patients to group N. We also evaluated the significance of the site of induction (the RVA or the RVOT) and the coupling interval of extrastimuli at the time of VA induction (<200 ms or  $\geq$ 200 ms) on the prognosis of the patients.

### Follow-up

An ICD implantation was proposed for all the patients with a previous VF and for those in whom VF or PVT was induced during the electrophysiological study. All patients were followed up in the outpatient clinic. Patients with and without ICD were followed up at every 3 and 6 months, respectively. Primary clinical outcome was determined as an occurrence of VF, sustained ventricular tachycardia, or sudden death.

### Statistical analysis

Data were analyzed with JMP 8.0 software package (SAS Institute, Inc, Cary, NC). Numeric values were expressed as mean  $\pm$  standard deviation.  $\chi^2$  test, Student's t test, or 1-way analysis of variance was performed when appropriate to test for statistical differences.  $P < .05$  was considered statistically significant. Event rate curves were plotted according to the Kaplan–Meier method and were analyzed with the log-

rank test. Univariate and multivariate Cox regression were performed to assess predictive values of factors for subsequent cardiac events.

## Results

### Electrophysiological study

VA was induced in 81 patients (VF in 71 and PVT in 10): in 4 by single extrastimulus, in 41 by double extrastimuli, and in 36 by triple extrastimuli. There were 45 patients in group SD, 36 in group T, and 27 in group N.

Patients' characteristics are presented in Table 2. There were no significant differences among the 3 groups in gender, age, history of VF or syncope, family history of BrS or sudden death under 45 years of age, and age at the first cardiac event. There were also no significant differences in ECG parameters of the RR interval, PQ interval, QRS duration, corrected QT interval, and incidence of *SCN5A* mutation. Spontaneous coved-type ST segment was the only factor with significantly higher incidence in group SD than in group T and group N. LAS40 tended to be longer and RMS40 tended to be smaller in group SD and group T than in group N.

**Table 2** Clinical, electrocardiographic, genetic, and electrophysiological characteristics

Characteristics	Group SD (n = 45)	Group T (n = 36)	Group N (n = 27)	P value
<b>Clinical</b>				
Male	44 (98%)	34 (94%)	26 (96%)	.73
Age (y)	48 $\pm$ 11	45 $\pm$ 13	44 $\pm$ 14	.31
Hx of VF	11 (24%)	9 (25%)	6 (22%)	.97
Hx of syncope	17 (38%)	13 (36%)	10 (37%)	.99
Asymptomatic	17 (38%)	14 (39%)	11 (41%)	.97
Family Hx of BrS	3 (7%)	0 (0%)	3 (11%)	.15
Family Hx of sudden death under age 45 y	10 (22%)	6 (17%)	6 (22%)	.80
Age at first CE (y)	44 $\pm$ 16	43 $\pm$ 14	41 $\pm$ 13	.86
<b>Electrocardiographic</b>				
RR interval (ms)	978 $\pm$ 125	990 $\pm$ 112	936 $\pm$ 108	.18
PQ interval (ms)	173 $\pm$ 27	178 $\pm$ 23	181 $\pm$ 39	.54
QRS duration (ms)	95 $\pm$ 15	99 $\pm$ 16	96 $\pm$ 19	.63
Corrected QT interval (ms)	404 $\pm$ 31	405 $\pm$ 26	406 $\pm$ 30	.97
Spontaneous coved-type ST segment	32 (71%)	19 (53%)	11 (41%)	.033
Total filtered QRS duration	122 $\pm$ 19	119 $\pm$ 16	114 $\pm$ 14	.17
LAS40	49 $\pm$ 16	49 $\pm$ 19	41 $\pm$ 13	.13
RMS40	14 $\pm$ 10	17 $\pm$ 10	20 $\pm$ 13	.051
Late potential*	32/44 (73%)	25/35 (71%)	13/24 (54%)	.25
<b>Genetic</b>				
<i>SCN5A</i> mutation	6 (13%)	3 (8%)	3 (11%)	.78
<b>Electrophysiological</b>				
AA interval	921 $\pm$ 153	903 $\pm$ 174	905 $\pm$ 143	.86
AH interval	106 $\pm$ 31	101 $\pm$ 21	108 $\pm$ 33	.65
HV interval	45 $\pm$ 12	44 $\pm$ 8	42 $\pm$ 9	.58
<b>Induction of ventricular arrhythmia</b>				
Ventricular fibrillation	40 (89%)	31 (86%)		NA
PVT >15 successive beats	5 (11%)	5 (14%)		NA
<b>Site of induction</b>				
Right ventricular apex	11 (24%)	13 (36%)		NA
Right ventricular outflow tract	34 (76%)	23 (64%)		NA

AH = atrio-His; BrS = Brugada syndrome; CE = cardiac event; HV = His-ventricular; Hx = history; NA = not available; PVT = polymorphic ventricular tachycardia; VF = ventricular fibrillation.

\*Late potential was considered present when the 2 criteria (LAS40 > 38 ms and RMS40 < 18  $\mu$ V) were fulfilled.

As for electrophysiological characteristics, AA, atrio-His, and His-ventricular intervals showed no significant differences among the 3 groups. VA was more frequently induced from the RVOT than from the RVA (57 [70%] vs 24 [30%], respectively).

### Subsequent cardiac events during follow-up

We recommended all patients with prior VF episode, group SD patients, and group T patients with prior syncope to undergo an ICD implantation. For asymptomatic group T patients, and group N patients without prior VF, ICD implantation was performed only for those who wanted it after informed consent. Forty-one of the 45 group SD patients (91%), 25 of the 36 group T patients (69%), and 13 of the 27 group N patients (48%) underwent an ICD implantation.

There were no deaths during  $82 \pm 48$  months of follow-up; 24 patients had VF events. All these 24 patients had undergone ICD implantation, and VF was documented on the recordings of the ICD. No patients without ICD experienced any syncope. There were no significant differences in the follow-up period among the 3 groups (group SD  $83 \pm 50$  months, group T  $81 \pm 44$ , and group N  $80 \pm 49$ ;  $P = .96$ ). Significantly more VF episodes occurred in group SD (16 of 45 [36%]) than in group T (3 of 36 [8%]) and in group N (5 of 27 [19%]) ( $P = .012$ ).

Figure 1 shows the results of the Kaplan-Meier analysis of subsequent cardiac events. As previously reported, induction of VA was not associated with subsequent cardiac events (Figure 1A, log-rank,  $P = .78$ ). When we focused on the


numbers of extrastimuli, group SD had a significantly higher risk of subsequent cardiac events than did group T (log-rank,  $P = .004$ ), but there were no significant differences in the subsequent cardiac event rate between group SD and group N and between group T and group N (Figure 1B). Among 82 patients without prior VF episode, VA induction with up to 2 extrastimuli was a significant risk factor of subsequent cardiac events (Figure 1C, log-rank,  $P = .003$ ).

In 81 patients with induced VA, the site of induction (the RVA or the RVOT) and the coupling interval of extrastimuli at the time of VA induction ( $<200$  ms or  $\geq 200$  ms) were not associated with subsequent cardiac events (Figures 2A and 2B, log-rank,  $P = .57$  and  $.52$ , respectively). The cardiac event rate was associated with the number of extrastimuli, not with the site of induction and the coupling interval (Figures 3A and 3B).


As for 42 asymptomatic patients, 2 of the 17 patients in group SD experienced subsequent VF episodes, whereas none of the 14 patients in group T and 11 in group N experienced subsequent cardiac events. Although the number of patients was small, group SD showed a significantly higher cardiac event rate than did group T and group N (log-rank,  $P = .046$ ).

### Predictors of long-term prognosis

The results of Cox regression analysis are shown in Table 3. In univariate Cox regression, history of VF, VA induced with up to 2 extrastimuli, incidence of spontaneous coved-type ST segment, and Late potential were significant predictors of subsequent cardiac events. Multivariate Cox re-



**Figure 1** Kaplan-Meier curves of subsequent cardiac events during follow-up. Kaplan-Meier curves of cardiac events (A) depending on the overall inducibility of ventricular arrhythmias (VFs and polymorphic ventricular tachycardia  $>15$  successive beats) by up to triple extrastimuli, (B) in the 3 groups, and (C) in the population of patients without history of VF depending on the 3 groups. Although the overall inducibility was not associated with subsequent cardiac events, inducibility by up to 2 extrastimuli had significant predictive values for the occurrence of subsequent cardiac events. Group SD had a significantly higher cardiac event rate than did group T. In the population of patients without previous VF, inducibility by up to 2 extrastimuli was strongly associated with subsequent cardiac events.



**Figure 2** Kaplan–Meier curves of subsequent cardiac events during follow-up. Kaplan–Meier curves of cardiac events (A) depending on the induction site and (B) the minimum coupling interval of extrastimuli at the time of induction. Neither the site of induction, the right ventricular outflow tract or the right ventricular apex, nor the minimum coupling interval, longer or shorter than 200 ms, was associated with subsequent cardiac events.

gression demonstrated that the only predictive index was VA induction with up to 2 extrastimuli except for history of VF. Neither VA induction from the RVA nor the coupling interval of extrastimuli <200 ms at the time of VA induction was a predictor of subsequent cardiac events.

**Discussion**

The major findings of the present study were the following: (1) induction of VA by triple extrastimuli was not associated with a higher incidence of subsequent VF, (2) patients with VA induced by up to 2 extrastimuli had significantly more frequent VF episodes during 7 years of follow-up, (3) neither the site of VA induction (the RVA or the RVOT) nor the coupling interval of VA induction (<200 ms or ≥200 ms) was associated with the incidence of subsequent cardiac events.

We evaluated the prognostic role of VA induction by PES and found that the number of extrastimuli that induced VA was prognostic for patients with Brugada type 1 ECG.

**Clinical significance of PES in patients with BrS**


Conflicting data have been reported from several registries as to the prognostic value of PES in patients with BrS.<sup>4,6,7</sup> Bru-

gada et al reported that PES was a good predictor of arrhythmic events. Meanwhile, Priori et al and Probst et al argued that it was not a useful index. Meta-analysis data indicated that PES was not useful for predicting subsequent cardiac events, and the published ACC/AHA/ESC guidelines referred to PES as a class IIb indication in asymptomatic patients with BrS for risk stratification.<sup>11–13</sup> However, there were several limitations for each registry such as the different PES protocols.<sup>14</sup> Moreover, these conflicting data may be related to the specific inclusion criteria of each registry. Recently, Giustetto et al<sup>9</sup> reported that PES protocol up to 2 extrastimuli with ventricular effective refractory period was useful in risk stratification in patients with BrS. This Italian study agrees with our result that VA induction with up to 2 extrastimuli could help predict subsequent cardiac events if a consistent PES protocol is used. The present study also demonstrated that a PES protocol with up to 3 extrastimuli was not useful for risk stratification in patients with BrS. We presume that this result in part explains why several registries reported conflicting data.

Patients without VA induction, especially patients with history of VF, had subsequent arrhythmic events in the present study (5 of 27 [19%]). In this respect, the present study differs from the Italian study. We can cite 2 contributing factors. First, our follow-up period was nearly 7 years, which was much longer than that of the Italian study. Second, we adopted only 1 basic cycle length, whereas Giustetto et al adopted 2 basic cycle lengths; hence, it is possible that we could not induce VA in some patients.

**Underlying mechanism**

Arrhythmogenicity in patients with BrS is possibly associated with both repolarization and depolarization abnormal-



**Figure 3** Incidence of subsequent cardiac events according to the number of extrastimuli, the site of induction, and the minimum coupling interval at the time of induction. Incidence of cardiac events (A) according to the number of extrastimuli and the site of induction and (B) the number of extrastimuli and the minimum coupling interval. The patients whose ventricular arrhythmias were induced by up to 2 extrastimuli had a higher incidence of cardiac events in both categories.

**Table 3** Predictive factors of subsequent cardiac events

	Univariate analysis		Multivariate analysis	
	Hazard ratio	P value	Hazard ratio	P value
Hx of VF	4.59 (2.05–10.7)	<.001	3.47 (1.50–8.27)	.004
VA induced with double extrastimuli	3.21 (1.41–7.92)	.005	3.03 (1.26–8.00)	.013
Spontaneous coved-type ST segment	3.20 (1.28–9.65)	.011	1.77 (0.67–5.56)	.26
Late potential	2.72 (1.02–9.40)	.046	1.77 (0.60–5.98)	.34
SCN5A mutation	2.92 (0.96–7.33)	.057	1.66 (0.47–4.63)	.40
VA induction at the RVA	1.29 (0.47–3.07)	.60		
VA induced with CI < 200 ms	0.86 (0.37–1.91)	.71		
VA induced by PES	1.21 (0.48–3.64)	.71		
Family Hx of sudden death under age 45	1.18 (0.39–2.95)	.74		

CI = coupling interval; Hx = history; PES = programmed electrical stimulation; RVA = right ventricular apex; VA = ventricular arrhythmia; VF = ventricular fibrillation. Parentheses represent 95% confidence interval.

ities. In the present study, patients with induced VA had longer LAS40 ( $49 \pm 17$  vs  $41 \pm 13$ ;  $P = .042$ ) and smaller RMS40 ( $15 \pm 10$  vs  $20 \pm 13$ ;  $P = 0.034$ ) than did noninduced patients, which may reflect depolarization abnormality and is concordant with our previous report.<sup>15</sup>

There have been several reports regarding depolarization abnormalities in BrS such as *SCN5A* mutation or fragmented QRS.<sup>16–18</sup> By using an experimental model, Aiba et al<sup>19</sup> showed that depolarization abnormalities played a significant role in VF maintenance. Thus, if PES results reflect depolarization abnormality, we could evaluate how easily VF continues through PES. The initiation of VF is thought to be due to phase 2 reentry-induced premature beats (repolarization abnormality).<sup>19,20</sup> It could be difficult to evaluate repolarization abnormality through PES, and this is why PES in BrS cannot completely predict subsequent cardiac events.

### Clinical implication

According to the ACC/AHA/ESC guidelines, patients with BrS with spontaneous ST-segment elevation and syncope are a class IIa indication for ICD implantation.<sup>13</sup> However, some patients with BrS experience neurally mediated syncope, as previously reported, which should be distinguished from syncope of unknown origin.<sup>21</sup> Therefore, only the history of syncope could lead to unnecessary use of ICD. We showed that PES of up to 2 extrastimuli can predict subsequent events of patients with prior syncope, demonstrating the possibility that PES could help reduce the unnecessary use of ICD in those patients (Figure 1C).

Meta-analysis studies of patients with BrS could not identify a significant role of PES for predicting subsequent arrhythmic events.<sup>11,12</sup> However, many registries included in their meta-analysis adopted PES protocol of up to 3 extrastimuli. Triple extrastimuli could induce VA even in normal individuals and exaggerate nonspecific depolarization abnormality leading to induction of nonspecific VA. This suggests that VA induction by triple extrastimuli may be highly unnatural, resulting in false-positive VA induction.

ACC/AHA/ESC guidelines have not yet delineated an appropriate PES protocol in detail, such as the number of extrastimuli. We showed that single extrastimulus or double

extrastimuli are adequate for PES for patients with BrS. Although the number of patients was small, VA induction with up to 2 extrastimuli was associated with subsequent arrhythmic events even in asymptomatic patients. Positive and negative predictive values according to PES protocols are shown in Table 4. Based on our criteria that VA induction was considered positive when VF or PVT with more than 15 successive beats was elicited, a protocol of up to 2 extrastimuli showed that the positive predictive value (PPV) was 36% and the negative predictive value (NPV) was 87%. On the other hand, a protocol of up to 3 extrastimuli showed that PPV was 23% and NPV was 81%. Even when we consider only VF as an induction criterion, both PPV and NPV were higher with up to 2 extrastimuli (Table 4). Based on our data, protocols up to 2 extrastimuli were sufficient for PES in patients with BrS. In the subgroup of 82 patients without prior VF or aborted cardiac arrest, VF occurred in 9 of the 34 patients with VA induced by up to 2 extrastimuli. No VF occurred in 27 patients with VA induced by triple extrastimuli, and only 1 of the 21 noninducible patients experienced VF. The PPV of PES protocol up to 2 extrastimuli was 26%, but the NPV was high at 98%. However, a low PPV of PES can cause unnecessary use of ICD implantation, especially for asymptomatic patients. We still need to make a decision based on several indices combined, as Delise et al<sup>22</sup> have recently reported.

**Table 4** Positive and negative predictive values according to protocols of PES

Protocols	PPV	NPV
VF and NSPVT >15 successive beats		
PES with up to 2 ExS	16/45 (36%)	55/63 (87%)
PES with up to 3 ExS	19/81 (23%)	22/27 (81%)
Only VF		
PES with up to 2 ExS	13/40 (33%)	57/68 (84%)
PES with up to 3 ExS	16/71 (23%)	29/37 (78%)

ExS = extrastimuli; NPV = negative predictive value; NSPVT = non-sustained polymorphic ventricular tachycardia; PES = programmed electrical stimulation; PPV = positive predictive value; VF = ventricular fibrillation.

## Study limitations

This study has several limitations. First, this was a retrospective study. However, we believe that our data have validity because this was not an interventional study but an observational study, and moreover, the follow-up periods of the 3 groups were not significantly different. Second, this study consisted of a small population of 108 patients, insufficient to fully evaluate the prognosis of patients with BrS. Further study with a larger number of patients with BrS and with consistent protocol of PES will be required to draw a firm conclusion on the importance of the number of extrastimuli. If each registry does not have a large enough number of patients, a meta-analysis that can compare the numbers of extrastimuli could validate the significance of PES. Third, we could have underestimated the cardiac event rate because the end point of the patients without ICD was based on symptoms (syncope); thus, asymptomatic cardiac events during sleep could be missed. Fourth, we adopted only 500 ms as a basic cycle length, and so VA could not be induced in some patients in the present study because this was shorter than in other studies that employed more than 2 basic cycle lengths. However, VA was induced in 75% and VF was induced in 68% of the patients. This induction rate was comparable to that in other registries; this suggests that a single basic cycle length of 500 ms is enough to induce VA. We did not deliver extrastimuli coupled with intervals shorter than 180 ms. Therefore, we could not assess the significance of delivering extrastimuli with intervals shorter than 180 ms. However, extra stimulus with shorter intervals may exaggerate nonspecific depolarization abnormality, leading to induction of nonspecific VA. This issue needs to be addressed. Fifth, the incidence of *SCN5A* mutation was relatively low at 11%, even though we searched the entire coding sequence of *SCN5A*. As previously pointed out, the incidence of *SCN5A* in Japan is lower than in Western countries, and so this study agrees with previous data.<sup>23,24</sup> Finally, there were 46 patients (7 with prior VF, 21 with prior syncope, and 18 asymptomatic) with drug-induced type 1 ECG, which can be misdiagnosed as BrS because of its false-positive ECG morphology. However, the percentage of these patients was lower than that in the FINGER study, and we confirmed the obvious coved ST elevation induced by sodium-channel-blocker test in patients with type 2 and type 3 ECG.

## Conclusion

The number of extrastimuli in PES that induced ventricular arrhythmias served as a prognostic indicator for patients with type 1 Brugada ECG. The site of induction and the coupling interval of extrastimuli at the time of VF induction were not prognostic indicators of patients with BrS. Our data suggest that PES in patients with type 1 Brugada ECG should employ up to 2 extrastimuli, rather than 3.

## References

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. *J Am Coll Cardiol* 1992;20:1391-1396.
2. Kamakura S, Ohe T, Nakazawa K, et al, for the Brugada Syndrome Investigators in Japan. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. *Circ Arrhythm Electrophysiol* 2009;2:495-503.
3. Brugada J, Brugada R, Antzelevitch C, et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. *Circulation* 2002;105:73-78.
4. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. *Circulation* 2002;105:1342-1347.
5. Ikeda T, Takami M, Sugi K, Mizusawa Y, Sakurada H, Yoshino H. Noninvasive risk stratification of subjects with a Brugada-type electrocardiogram and no history of cardiac arrest. *Ann Noninvasive Electrocardiol* 2005;10:396-403.
6. Makimoto H, Nakagawa E, Takaki H, et al. Augmented ST-segment elevation during recovery from exercise predicts cardiac events in patients with Brugada syndrome. *J Am Coll Cardiol* 2010;56:1576-1584.
7. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry. *Circulation* 2010;121:635-643.
8. Brugada P, Brugada R, Mont L, Rivero M, Geelen P, Brugada J. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. *J Cardiovasc Electrophysiol* 2003;14:455-457.
9. Giustetto C, Drago S, Demarchi PG, et al. Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study. *Europace* 2009;11:507-513.
10. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation* 2005;111:659-670.
11. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. *J Cardiovasc Electrophysiol* 2006;17:577-583.
12. Paul M, Gersch J, Schulze-Bahr E, et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. *Eur Heart J* 2007;28:2126-2133.
13. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Circulation* 2006;114:e385-e484.
14. Gasparini M, Priori SG, Mantica M, et al. Programmed electrical stimulation in Brugada syndrome: how reproducible are the results? *J Cardiovasc Electrophysiol* 2002;13:880-887.
15. Kanda M, Shimizu W, Matsuo K, et al. Electrophysiologic characteristics and implications of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. *J Am Coll Cardiol* 2002;39:1799-1805.
16. Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate *SCN5A*-related patients from non-*SCN5A*-related patients. *J Am Coll Cardiol* 2002;40:350-356.
17. Yokokawa M, Noda T, Okamura H, et al. Comparison of long-term follow-up of electrocardiographic features in Brugada syndrome between the *SCN5A*-positive probands and the *SCN5A*-negative probands. *Am J Cardiol* 2007;100:649-655.
18. Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. *Circulation* 2008;118:1697-1704.
19. Aiba T, Shimizu W, Hidaka I, et al. Cellular basis for trigger and maintenance of ventricular fibrillation in the Brugada syndrome model: high-resolution optical mapping study. *J Am Coll Cardiol* 2006;47:2074-2085.
20. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. *Circulation* 1999;100:1660-1666.
21. Yokokawa M, Okamura H, Noda T, et al. Neurally mediated syncope as a cause of syncope in patients with Brugada electrocardiogram. *J Cardiovasc Electrophysiol* 2010;21:186-192.
22. Delise P, Allocca G, Marras E, et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. *Eur Heart J* 2011;32:169-176.
23. Hiraoka M. Inherited arrhythmic disorders in Japan. *J Cardiovasc Electrophysiol* 2003;14:431-434.
24. Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the *SCN5A*-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. *Heart Rhythm* 2010;7:33-46.

# Effect of sodium-channel blockade on early repolarization in inferior/lateral leads in patients with idiopathic ventricular fibrillation and Brugada syndrome

Hiro Kawata, MD,\*<sup>†</sup> Takashi Noda, MD, PhD,\* Yuko Yamada, MD,\* Hideo Okamura, MD,\* Kazuhiro Satomi, MD, PhD,\* Takeshi Aiba, MD, PhD,\* Hiroshi Takaki, MD,\* Naohiko Aihara, MD,\* Mitsuaki Isobe, MD, PhD,<sup>†</sup> Shiro Kamakura, MD, PhD,\* Wataru Shimizu, MD, PhD\*

From the \*Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; <sup>†</sup>Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

**BACKGROUND** A high incidence of early repolarization (ER) pattern in the inferolateral leads has been reported in patients with idiopathic ventricular fibrillation (IVF). Brugada syndrome (BS) is characterized by J-point or ST-segment elevation in the right precordial leads and ventricular fibrillation, and some patients with BS also have ER in the inferolateral leads.

**OBJECTIVE** To compare the clinical characteristics and effects of sodium-channel blockade on ER between IVF patients with ER (early repolarization syndrome [ERS]) and BS patients with or without ER.

**METHODS** Fourteen patients with ERS and 21 patients with BS were included in this study. ER was defined as an elevation of at least 0.1 mV from baseline in the QRS-T junction in the inferolateral leads. Provocative tests with sodium-channel blockers were conducted in all patients with ERS to distinguish ERS from BS.

**RESULTS** In the ERS group, all patients were male and most patients experienced ventricular fibrillation during sleep or low activity (79%). ER was attenuated by sodium-channel blockers in most patients with ERS (13/14, 93%) and BS (5/5, 100%), whereas ST-segment elevation was augmented in the right precordial leads in the BS group. The rates of positive late potentials

were significantly higher in the BS group (60%) than in the ERS group (7%) ( $P < .01$ ).

**CONCLUSIONS** Some similarities were observed between ERS and BS, including gender, arrhythmia triggers, and response of ER to sodium-channel blockers. Unlike the ST segment in the right precordial leads in BS, ER was attenuated in patients with both ERS and BS, suggesting a differential mechanism between ER in the inferolateral leads and ST elevation in the right precordial leads.

**KEYWORDS** Early repolarization; J wave; Idiopathic ventricular fibrillation; Brugada syndrome; Sudden death; Sodium-channel blocker

**ABBREVIATIONS** BS = Brugada syndrome; ECG = electrocardiogram; ER = early repolarization; ERS = early repolarization syndrome; IVF = idiopathic ventricular fibrillation; LPs = late potentials; QTc = corrected QT interval; SAECG = signal-averaged electrocardiogram; SCD = sudden cardiac death; VF = ventricular fibrillation; VT = ventricular tachycardia

(Heart Rhythm 2012;9:77-83) © 2012 Heart Rhythm Society. All rights reserved.

## Introduction

Early repolarization (ER) pattern is often found in the general population and has been considered a benign electrocardiographic finding. Its prevalence has been estimated to

be between 1% and 5% of healthy adults.<sup>1-4</sup> Idiopathic ventricular fibrillation (IVF) presenting prominent ST-segment elevation in the inferior leads has been considered as a variant of Brugada syndrome (BS).<sup>5,6</sup> BS<sup>7</sup> is characterized by ST-segment elevation in the right precordial leads V1 to V3 and is considered to have a high propensity toward sudden cardiac death (SCD).<sup>8,9</sup> Recently, several reports have suggested the association of IVF with ER in the inferior and/or lateral lead in the electrocardiogram (ECG).<sup>3,10-14</sup> ER is reported to be found more frequently among patients with IVF than among healthy control subjects.<sup>10,15</sup> However, little is known about the clinical and electrocardiographic characteristics and the pharmacological response of ER in patients with IVF and BS associated with ER and their different re-

Dr Shimizu was supported in part by the Research Grant for the Cardiovascular Diseases (21C-8, 22-4-7, H23-114) from the Ministry of Health, Labour and Welfare, Japan, and Grant-in-Aid for Scientific Research on Innovative Areas (22136011). This article was presented in part at the American Heart Association 2010, Chicago, Illinois, November 13-17, 2010, and published as an abstract (Circulation 2010;122:A14948). Address for reprints and correspondence: Dr Wataru Shimizu, MD, PhD, Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. E-mail address: wshimizu@hsp.ncvc.go.jp.

sponse from that of ST elevation in the right precordial leads in patients with BS. The present study aimed to investigate the similarities and differences between IVF with ER (early repolarization syndrome [ERS]) and BS with or without ER.

## Methods

### Patient characteristics

Among 38 patients with IVF, admitted to the National Cerebral and Cardiovascular Center between 1994 and 2009, ER in the inferior and/or lateral ECG leads was recorded in 14 patients (37%). These 14 patients were included in this study as an ERS group (all males, aged 27–64 years, mean age  $44.7 \pm 13.6$  years). Twenty-one patients with BS with a history of ventricular fibrillation (VF) or aborted SCD were also included in this study. According to the published guidelines,<sup>16,17</sup> patients were diagnosed as suffering from IVF if they had no structural heart disease confirmed by noninvasive studies (physical examination, ECG, exercise stress test, echocardiogram, and cardiac magnetic resonance imaging or computed tomography) and invasive studies (coronary angiography and left ventricular cineangiography). Long QT syndrome (corrected QT [QTc] interval  $\geq 440$  millisecond), short QT syndrome (QTc interval  $< 340$  millisecond), and BS were also excluded to diagnose a patient as suffering from IVF. To exclude BS, all subjects in the ERS group were proven to be negative with a pharmacological challenge with pilsicainide.<sup>8,18</sup>

The BS group consisted of 21 patients (19 males, aged 20–64 years, mean age  $39.7 \pm 12.6$  years) with an episode of documented VF or aborted SCD. Eleven had a sponta-


neous type 1 ECG, and in the remaining, it was induced by a sodium-channel blocker. Ethical approval of the present study was obtained from the Institutional Review Committee of the National Cerebral and Cardiovascular Center.

### Electrocardiography

All available conventional ECGs (25 mm/s, 10 mm/mV) were investigated in the search for ER. ER was defined as an elevation of at least 1 mm (0.1 mV) in the J point (QRS–ST junction) in at least 2 leads (Figure 1), either as QRS slurring (smooth transition from QRS to the ST segment) or as notching (a positive J deflection inscribed on the S wave).<sup>10</sup> The inferior (II, III, and aVF) and lateral (I, aVL, and V4–V6) leads were evaluated. To exclude BS, no J-point elevation must exist in the right precordial leads (V1–V3).

All ECGs were interpreted blindly by 2 independent cardiologists (H.K., W.S.). The following parameters were assessed in lead II, which include P-wave duration and PQ and RR intervals. QRS duration and QT interval were assessed in leads II and V5. The QTc interval was calculated using Bazett's method. The amplitude of ER was assessed in the inferior leads (II, III, and aVF), the lateral leads (I, aVL, and V4–V6), or both, and the maximum ER amplitude was measured. We selected leads II and V5 as representative of inferior and lateral leads for the analysis of ER amplitude.

BS was diagnosed when a type 1 coved-type ST-segment elevation ( $\geq 0.2$  mV at J point) was observed in  $>1$  of the right precordial leads (V1–V3) in the presence or absence of



**Figure 1** A: Twelve-lead ECG in a patient with early repolarization syndrome. ER (arrow) was seen in the lateral leads (V4–V6) under baseline conditions. B: Monitor ECG recorded during the arrhythmic periods in the same patient showed a consistent increase in the amplitude of ER, followed by initiation of ventricular fibrillation. ECG, electrocardiogram; ER, early repolarization.

a sodium-channel blocker in conjunction with documented VF or polymorphic ventricular tachycardia (VT).

**Drug challenge test**

The drug challenge test was performed with intravenous pilsicainide (1 mg/kg, maximum 50 mg, 5 mg/min) or flecainide (2 mg/kg, maximum 100 mg, 10 mg/min). The test result was considered positive if a type 1 Brugada ECG appeared in >1 right precordial lead (V1–V3). Once again, we excluded all patients with IVF but without sodium-channel blocker challenge test from our study to clarify the diagnosis of ERS.

**Late potentials**

Late potentials (LPs) were analyzed by using a signal-averaged electrocardiogram (SAECG) system (Arrhythmia Research Technology 1200EPX, Milwaukee, WI). Three parameters were assessed by using a computer algorithm: (1) total filtered QRS duration (f-QRS), (2) duration of low-amplitude signals <40 μV of the filtered QRS complex (LAS<sub>40</sub>), and (3) root-mean-square voltage of the terminal 40 millisecond of the filtered QRS complexes (RMS<sub>40</sub>). LPs were considered positive when at least 2 of the 3 parameters were abnormal: f-QRS >120 millisecond, LAS<sub>40</sub> >38 millisecond, and RMS<sub>40</sub> <18 μV.

**Statistical analysis**

Continuous variables were expressed as mean value ± SD. A comparison between the 2 groups was performed with Student’s t test for paired data. Categorical variables were compared with Fisher’s exact test. A P value of <.05 was regarded as being significant.

**Results**

**Clinical and electrocardiographic characteristics**

In the BS group, 9 of the 21 patients (43%) with BS showed ER in the inferior and/or lateral leads. A comparison of the clinical and electrocardiographic characteristics of the 14 ERS group patients, 21 BS group patients, and 9 BS patients with ER is shown in Table 1. The average age of 9 BS patients with ER was lower than that of the ERS group. Except for that, no significant differences were observed in baseline clinical characteristics with respect to age, gender, family history of SCD, and activity at the time of cardiac arrest. The number of premature ventricular complexes during 24-hour Holter ECG was not different between the 2 groups.

Regarding SAECG parameters, the values of f-QRSd, LAS<sub>40</sub>, and RMS<sub>40</sub> in 14 ERS group patients were 97.8 ± 8.1 millisecond, 29.8 ± 5.2 μV, and 50.0 ± 24.2 millisecond, respectively. The corresponding values in 21 BS group patients were 119.8 ± 17.3 millisecond, 47.0 ± 19.2 μV, and 17.8 ± 13.4 millisecond, respectively. All these parameters were significantly different between the 2 groups. LPs were positive in 1 of the 14 patients (7%) in the ERS group and in 12 of the 20 patients (60%) in the BS group. The rate of positive LPs was significantly higher in the BS group than in the ERS group (P <.01). We also compared the SAECG parameters and the rate of positive LPs between 14 ERS group patients and 9 BS patients with ER. The tendency was similar to the comparison between 14 ERS group patients and 21 BS group patients; however, there were no significant differences in the LAS<sub>40</sub> and rate of LPs because of the small number of BS patients with ER.

**Table 1** Clinical and electrocardiographic characteristics in the early repolarization syndrome group, the Brugada syndrome group, and the Brugada syndrome with ER group

	Group			P value	
	ERS (n = 14)	BS (n = 21)	BS with ER (n = 9)	ERS vs BS	ERS vs BS with ER
<b>Clinical characteristics</b>					
Age (y), mean ± SD	44.7 ± 13.6	39.7 ± 12.6	33.3 ± 10.3	NS	.045
Male gender, n/N	14/14	19/21	7/9	NS	NS
Family history of sudden cardiac death, n/N (%)	0/14 (0%)	1/21 (5%)	1/9 (11%)	NS	NS
<b>Activity at the time of cardiac arrest, n (%)</b>					
Sleep	3 (21%)	9 (42%)	5 (55%)	NS	NS
Rest	8 (57%)	10 (48%)	3 (33%)	NS	NS
Others	3 (21%)	2 (10%)	1 (11%)	NS	NS
<b>Electrocardiographic characteristics</b>					
Presence of ER, n/N (%)	14/14 (100%)	9/21 (43%)	9/9 (100%)	<.01	NS
Holter ECG, PVC in 24 h, mean ± SD	49.4 ± 169.3	1.9 ± 4.2	2.3 ± 4.4	NS	NS
<b>Signal-averaged electrocardiography, mean ± SD</b>					
f-QRSd (ms)	97.8 ± 8.1	119.8 ± 17.3	111.6 ± 11.5	<.0001	<.01
LAS <sub>40</sub> (μV)	29.8 ± 5.2	47.0 ± 19.2	33.8 ± 14.5	<.01	NS
RMS <sub>40</sub> (ms)	50.0 ± 24.2	17.8 ± 13.4	23.4 ± 14.2	<.0001	<.01
Abnormal SAECG, n/N (%)	1/14 (7%)	12/20 (60%)	4/9 (44%)	<.01	NS

Percentages may not total 100 because of rounding.

BS, Brugada syndrome; ECG, electrocardiogram; ER, early repolarization; ERS, early repolarization syndrome; f-QRSd, filtered QRS duration; LAS<sub>40</sub>, duration of low-amplitude signals <40 μV of QRS in the terminal filtered QRS complex; NS, not significant; PVC, premature ventricular contraction; RMS<sub>40</sub>, root-mean-square voltage of the terminal 40 millisecond of the filtered QRS complex; SAECG, signal-averaged ECG.



**Table 2** Baseline electrocardiographic parameters and their changes after administration of a sodium-channel blocker in the early repolarization syndrome group, the Brugada syndrome group, and the Brugada syndrome with ER group<sup>†</sup>

	Mean $\pm$ SD			P value	
	ERS (n = 14)	BS (n = 12)	BS with ER (n = 5)	ERS vs BS	ERS vs BS with ER
RR II (ms)	951 $\pm$ 116	930 $\pm$ 116	1024 $\pm$ 46	NS	NS
$\Delta$ RR II (ms)	-71 $\pm$ 41	-12 $\pm$ 17	-32 $\pm$ 62	<.05	NS
P II (ms)	104 $\pm$ 19	110 $\pm$ 16	112 $\pm$ 13	NS	NS
$\Delta$ P II (ms)	10 $\pm$ 9	21 $\pm$ 13	24 $\pm$ 16	<.05	<.05
PQ II (ms)	179 $\pm$ 34	191 $\pm$ 33	178 $\pm$ 28	NS	NS
$\Delta$ PQ II (ms)	30 $\pm$ 9	28 $\pm$ 14	38 $\pm$ 8	NS	NS
QRS II (ms)	90 $\pm$ 13	97 $\pm$ 18	90 $\pm$ 20	NS	NS
$\Delta$ QRS II (ms)	10 $\pm$ 10	23 $\pm$ 21	14 $\pm$ 21	NS	NS
QRS V5 (ms)	84 $\pm$ 8	91 $\pm$ 19	82 $\pm$ 21	NS	NS
$\Delta$ QRS V5 (ms)	13 $\pm$ 8	29 $\pm$ 18	28 $\pm$ 8	<.05	<.01
QT II (ms)	377 $\pm$ 19	370 $\pm$ 14	374 $\pm$ 15	NS	NS
$\Delta$ QT II (ms)	10 $\pm$ 14	28 $\pm$ 18	16 $\pm$ 5	NS	NS
QTcII (ms)	388 $\pm$ 20	385 $\pm$ 24	370 $\pm$ 13	NS	NS
$\Delta$ QTcII (ms)	10 $\pm$ 14	29 $\pm$ 18	16 $\pm$ 5	<.05	NS
QT V5 (ms)	376 $\pm$ 26	372 $\pm$ 17	376 $\pm$ 15	NS	NS
$\Delta$ QT V5 (ms)	6 $\pm$ 18	38 $\pm$ 23	14 $\pm$ 11	<.01	NS
QTcV5 (ms)	387 $\pm$ 23	387 $\pm$ 24	372 $\pm$ 12	NS	NS
$\Delta$ QTcV5 (ms)	7 $\pm$ 19	40 $\pm$ 25	14 $\pm$ 11	<.01	NS

BS = Brugada syndrome; ER = early repolarization; ERS = early repolarization syndrome; P = P-wave duration; PQ = PQ interval; QRS = QRS duration; QT = QT interval; QTc = corrected QT interval; RR = RR interval.

### Sodium-channel blocker infusion test

The sodium-channel blocker infusion test was performed in 12 of the 21 patients with BS, and the test result was positive in all 12 patients. We compared the pharmacological responses of several ECG parameters to a sodium-channel blocker between 14 patients with ERS and 12 patients with BS (Table 2). There were no significant differences in the baseline ECG parameters, including RR interval, P-wave duration, PQ interval, QRS duration, and QT interval in any leads. Shortening of RR ( $\Delta$ RR II) was significantly larger in the ERS group. Prolongation of P-wave duration ( $\Delta$ P II), QRS duration ( $\Delta$ QRS V5), and QTc interval ( $\Delta$ QTc II,  $\Delta$ QTc V5) was significantly larger in the BS group compared with that in the ERS group.

Among 9 BS patients with ER, the sodium-channel blocker test was performed in 5 patients. We also compared the ECG parameters between 14 ERS group patients and 5 BS patients with ER (Table 2). Prolongation of P-wave duration ( $\Delta$ P II) and QRS duration ( $\Delta$ QRS V5) was significantly larger in the BS with ER group compared with that in the ERS group.

The ER amplitude and its responses to sodium-channel blockers between 14 ERS group patients and 5 BS patients with ER are shown in Table 3. In the ERS group, ER was observed in the inferior leads (II, III, and aVF) in 9 patients, in the lateral leads (I, aVL, and V4-V6) in 8 patients, and in both the inferior and lateral leads in 3 patients. In the 9 BS patients with ER, ER was observed in the inferior leads in 6 patients, in the lateral leads in 8 patients, and in both the inferior and lateral leads in 5 patients. The baseline maximum ER amplitude among the inferolateral leads (pre-ER max) in the BS group tended to be higher than in the ERS group (0.244  $\pm$  0.082 vs 0.162  $\pm$  0.069 mV;  $P = .057$ ). The

baseline ER amplitude in the inferior lead (pre-ER II) was significantly higher in the BS group than in the ERS group (0.236  $\pm$  0.081 vs 0.120  $\pm$  0.033 mV;  $P < .05$ ). After administration of a sodium-channel blocker, the ER ampli-

**Table 3** Amplitude of ER in leads II and V5 before and after the administration of a sodium-channel blocker test in the early repolarization syndrome group and the Brugada syndrome with ER group

Maximum amplitude of ER in any inferolateral leads (mV)	Mean $\pm$ SD			P value
	ERS (n = 14)	BS with ER (n = 5)		
Pre-ER max	0.162 $\pm$ 0.069	0.244 $\pm$ 0.082		NS
Post-ER max	0.081 $\pm$ 0.061*	0.124 $\pm$ 0.096*		NS
$\Delta$ ER	0.080 $\pm$ 0.067	0.120 $\pm$ 0.058		NS

Amplitude of ER in the inferior lead (II) (mV)	Mean $\pm$ SD		P value
	ERS (n = 9)	BS (n = 5)	
Pre-ER II	0.120 $\pm$ 0.033	0.236 $\pm$ 0.081	<.05
Post-ER II	0.091 $\pm$ 0.054*	0.104 $\pm$ 0.086*	NS
$\Delta$ ER II	0.028 $\pm$ 0.051	0.132 $\pm$ 0.068	<.05

Amplitude of ER in the lateral lead (V5) (mV)	Mean $\pm$ SD		P value
	ERS (n = 8)	BS (n = 5)	
Pre-ER V5	0.116 $\pm$ 0.032	0.215 $\pm$ 0.092	NS
Post-ER V5	0.010 $\pm$ 0.022*	0.137 $\pm$ 0.094*	NS
$\Delta$ ER V5	0.106 $\pm$ 0.026	0.077 $\pm$ 0.071	NS

BS = Brugada syndrome; ER = early repolarization; ERS = early repolarization syndrome; max = maximum; pre = before sodium-channel blocker test; post = after sodium-channel blocker infusion;  $\Delta$  = change. \* $P < .05$  vs pre.


tude was attenuated in all 5 patients with BS (100%) and in 13 of 14 patients with ERS (93%). ER attenuation was occasionally associated with the appearance of an S wave in both the groups (Figure 2). Therefore, the maximum ER amplitude (ER max), ER amplitude in the inferior lead (ER II), and ER amplitude in the lateral lead (ER V5) all were significantly decreased after the administration of sodium-channel blockers ( $P < .05$ ). Figure 3 illustrates the differential response to sodium-channel blockers between the ER in the inferolateral leads and the J point and ST segment in the right precordial leads in a patient with BS. The coved-type (type 1) ECG was unmasked and the J point in the right precordial leads (V1–V3) was augmented by the sodium-channel blocker, whereas the ER amplitude in the inferolateral leads (II, III, aVF, and V4–V6) was attenuated (Figure 3B).

### Discussion


The ER pattern in the inferior and/or lateral leads had been considered benign, and it is often found in healthy young individuals. Recently, several reports have attracted increasing attention to the association of IVF with ER in the inferior and/or lateral leads.<sup>5,10,19–21</sup> Haissaguerre et al<sup>10</sup> reported that ER was more frequently recognized in patients with IVF than in control subjects and that there was a higher incidence of recurrent VF in case subjects with ER than in those without. Rosso et al<sup>15</sup> also reported that ER was found more frequently among patients with IVF than among healthy control subjects. On the other hand, BS is also

characterized by a high incidence of VF without structural heart disease. The Brugada Consensus Report proposed that type 1 coved-type ST-segment elevation in the right precordial lead (V1–V3) in the absence or presence of a sodium-channel blocker was required to diagnose BS.<sup>22</sup> Considering this diagnostic criterion, the sodium-channel blocker challenging test is essential to exclude BS. In order to investigate pure ERS, the sodium-channel blocker challenging test should be performed before the diagnosis of ERS. Unlike previous studies,<sup>10,15</sup> we conducted the sodium-channel blocker challenging test in all 14 patients with ERS to exclude BS in the present study.

Intravenous administration of sodium-channel blockers has been used to unmask the Brugada ECG pattern in patients with BS.<sup>23</sup> On the other hand, in most patients associated with ER in both the ERS group and the BS group of the present study, the administration of a sodium-channel blocker induced the attenuation or disappearance of the ER and appearance of an S wave. Attenuation of the ER in the inferolateral leads appears to be due largely to a slowing of the transmural conduction so that inscription of the ER occurs later on the descending limb of the QRS in both the ERS group and the BS group. The S-wave appearance in the inferolateral leads is also probably due to the conduction delay induced by sodium-channel blockers. This may indicate the differential mechanism between Brugada-type ST elevation in the right precordial lead of BS and ER in the inferolateral leads in both groups.



**Figure 2** Twelve-lead ECGs in a patient with early repolarization syndrome under baseline conditions (A) and after pilsicainide administration (B). ER was seen in the lateral leads (I, aVL, and V4–V5) under baseline conditions (A, arrows). Intravenous administration of 30 mg of pilsicainide induced attenuation of ER and appearance of an S wave in the lateral leads (dashed arrows). Numbers above the arrows indicate the amplitude of ER. ECG, electrocardiogram; ER, early repolarization; S, S wave.



**Figure 3** Twelve-lead ECGs in a patient with Brugada syndrome under baseline conditions (A) and after pilsicainide administration (B). ER was seen in the inferior (II, III, and aVF) and lateral (V4–V6) leads under baseline conditions (A, arrows). Intravenous administration of 30 mg of pilsicainide unmasked coved-type Brugada ECG and remarkably augmented the J point and ST segment in the right precordial leads (V1–V3) (B, dashed arrows), while ER was attenuated in the inferior and lateral leads (B, arrows). Numbers above the arrows indicate the amplitude of ER. ECG, electrocardiogram; ER, early repolarization.

Antzelevitch and Gan-Xin<sup>24</sup> have proposed a new concept that an outward shift in repolarizing current due to a decrease in sodium- or calcium-channel currents or an increase in outward currents such as a transient outward potassium current ( $I_{to}$ ) can give rise to J-wave syndromes, which includes BS, ERS, hypothermia, and acute ischemia-induced VF. A prominent and pathological J wave, a slow upright deflection between the end of the QRS complex and the early portion of the ST segment, has been reported to be seen often in hypothermia.<sup>25</sup> However, the terms J-wave syndromes and ERS have not been properly defined.<sup>26</sup>

In some patients with BS of this study, type 1 Brugada ECG was unmasked by a sodium-channel blocker in the right precordial lead, while ER was attenuated in the inferolateral leads (Figure 3). Once again, this finding suggested the differential mechanism between Brugada-type ECG in the right precordial lead and ER in the inferolateral leads.

Moreover, as with a previous report,<sup>27</sup> the BS group showed significantly larger prolongation of P-wave duration, QRS duration, and QTc interval compared with the ERS group after a sodium-channel blocker infusion. Basic electrophysiology including animal or mathematical models must play an important role in determining whether the cellular mechanism of ST-segment elevation in the right precordial leads in BS and that of ER in the inferolateral leads in both ERS and BS differ or not.

Our study showed clinical characteristics of ERS to be similar to those of BS, including adult onset, male preponderance, cardiac events occurred at rest or during sleep, and

rare ventricular arrhythmias on Holter ECG.<sup>28,29</sup> On the other hand, some apparent differences were found between the 2 groups, including LPs on the SAECG. All 3 parameters of the SAECG were significantly different between the 2 groups, and the positive rate of LPs was significantly lower in the ERS group than in the BS group. The rate of LPs has been previously reported to be high in BS.<sup>30</sup> On the other hand, Haissaguerre et al<sup>10</sup> also reported a relatively low rate (11%) of LPs in patients with ERS. LPs are reported to be not only highly prevalent in BS but also independent predictors of VT/VF inducibility.<sup>27,31–33</sup> LPs are also considered to be linked to VF inducibility during electrophysiological study and ventricular conduction delay during VF induction in patients with BS<sup>28,34</sup> as well as in patients with VT/VF associated with organic heart diseases. The ST-segment elevation in the right precordial leads and arrhythmogenicity in BS can be explained by both repolarization and depolarization abnormalities in right ventricular outflow.<sup>9,35</sup> The presence of LPs can be caused by conduction delay (depolarization abnormality) in the ventricle including the right ventricular outflow tract. On the other hand, from the experimental studies, LPs are explained on the basis of repolarization abnormality (late phase 2 upstroke and concealed phase 2 reentry) in the right ventricular outflow tract.<sup>36</sup> In the present study, the lower prevalence of LPs in the ERS group may indicate a differential substrate for VF in patients with ERS compared with that in patients with BS.

## Conclusions

ER can be seen in some patients with IVF and in a subgroup of subjects with BS. Clinical similarities among them exist, including age, gender, and arrhythmia triggers. Response to sodium-channel blockade on ER in the inferolateral leads is the same in both groups: a consistent diminution in ER amplitude. This effect contrasts with the ST-segment elevation that is always observed in the right precordial leads in BS, thus arguing for different pathophysiological mechanisms.

## References

- Klatsky AL, Oehm R, Cooper RA, Udaltsova N, Armstrong MA. The early repolarization normal variant electrocardiogram: correlates and consequences. *Am J Med* 2003;115:171–177.
- Mehta M, Jain AC, Mehta A. Early repolarization. *Clin Cardiol* 1999;22:59–65.
- Gussak I, Antzelevitch C. Early repolarization syndrome: clinical characteristics and possible cellular and ionic mechanisms. *J Electrocardiol* 2000;33:299–309.
- Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome associated with early repolarization on electrocardiography. *N Engl J Med* 2009;361:2529–2537.
- Kalla H, Yan GX, Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant? *J Cardiovasc Electrophysiol* 2000;11:95–98.
- Takagi M, Aihara N, Takaki H, et al. Clinical characteristics of patients with spontaneous or inducible ventricular fibrillation without apparent heart disease presenting with J wave and ST segment elevation in inferior leads. *J Cardiovasc Electrophysiol* 2000;11:844–848.
- Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. *J Am Coll Cardiol* 1992;20:1391–1396.
- Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation* 2005;111:659–670.
- Shimizu W, Aiba T, Kamakura S. Mechanisms of disease: current understanding and future challenges in Brugada syndrome. *Nat Clin Pract Cardiovasc Med* 2005;2:408–414.
- Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. *N Engl J Med* 2008;358:2016–2023.
- Aizawa Y, Tamura M, Chinushi M, et al. Idiopathic ventricular fibrillation and bradycardia-dependent intraventricular block. *Am Heart J* 1993;126:1473–1474.
- Ogawa M, Kumagai K, Yamanouchi Y, Saku K. Spontaneous onset of ventricular fibrillation in Brugada syndrome with J wave and ST-segment elevation in the inferior leads. *Heart Rhythm* 2005;2:97–99.
- Potet F, Mabo P, Le Coq G, et al. Novel brugada SCN5A mutation leading to ST segment elevation in the inferior or the right precordial leads. *J Cardiovasc Electrophysiol* 2003;14:200–203.
- Shinohara T, Takahashi N, Saikawa T, Yoshimatsu H. Characterization of J wave in a patient with idiopathic ventricular fibrillation. *Heart Rhythm* 2006;3:1082–1084.
- Rosso R, Kogan E, Belhassen B, et al. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. *J Am Coll Cardiol* 2008;52:1231–1238.
- Zipes DP, Wellens HJ. Sudden cardiac death. *Circulation* 1998;98:2334–2351.
- Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. Survivors of out-of-hospital cardiac arrest with apparently normal heart: need for definition and standardized clinical evaluation. *Circulation* 1997;95:265–272.
- Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. *Circulation* 2000;101:510–515.
- Sinner FM, Reinhard W, Müller M, et al. Association of early repolarization pattern on ECG with risk of cardiac and all-cause mortality: a population-based prospective cohort study (MONICA/KORA). *PLoS Med* 2010;7:e1000314.
- Haruta D, Matsuo K, Tsuneto A, et al. Incidence and prognostic value of early repolarization pattern in the 12-lead electrocardiogram. *Circ Arrhythm Electrophysiol* 2011;123:2931–2937.
- Noseworthy PA, Tikkanen JT, Porthan K, et al. The early repolarization pattern in the general population: clinical correlates and heritability. *J Am Coll Cardiol* 2011;31:2284–2289.
- Wilde AAM, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. *Circulation* 2002;106:2514–2519.
- Brugada J, Brugada P. Further characterization of the syndrome of right bundle branch block, ST segment elevation, and sudden cardiac death. *J Cardiovasc Electrophysiol* 1997;8:325–331.
- Antzelevitch C, Gan-Xin Y. J wave syndromes. *Heart rhythm* 2010;7:549–558.
- Surawicz B, Knilans T. *Chou's Electrocardiography in Clinical Practice: Adult and Pediatric*. 6th ed. Philadelphia: WB Saunders; 2008.
- Surawicz B, Macfarlane PW. Inappropriate and confusing electrocardiographic terms: J-wave syndromes and early repolarization. *J Am Coll Cardiol* 2011;57:1584–1586.
- Shimizu W, Antzelevitch C, Suyama K, et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. *J Cardiovasc Electrophysiol* 2000;11:1320–1329.
- Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. *Eur Heart J* 1999;20:465–470.
- Corrado D, Basso C, Buja G, Nava A, Rossi L, Thiene G. Right bundle branch block, right precordial ST-segment elevation, and sudden death in young people. *Circulation* 2001;103:710–717.
- Ajio Y, Hagiwara N, Kasanuki H. Assessment of markers for identifying patients at risk for life-threatening arrhythmic events in Brugada syndrome. *J Cardiovasc Electrophysiol* 2005;16:45–51.
- Meregalli PG, Wilde AAM, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? *Cardiovasc Res* 2005;67:367–378.
- Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. *Circulation* 1997;96:2595–2600.
- Ikeda T, Sakurada H, Sakabe K, et al. Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification. *J Am Coll Cardiol* 2001;37:1628–1634.
- Kanda M, Shimizu W, Matsuo K, et al. Electrophysiologic characteristics and implications of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. *J Am Coll Cardiol* 2002;39:1799–1805.
- Yokokawa M, Noda T, Okamura H, et al. Comparison of long-term follow-up of electrocardiographic features in Brugada syndrome between the SCN5A-positive probands and the SCN5A-negative probands. *Am J Cardiol* 2007;100:649–655.
- Wilde AAM, Postema PG, Di Diego JM, et al. The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. *J Mol Cell Cardiol* 2010;49:543–553.